Daniel George Wildman - 22 Jun 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship: Director
Issuer ticker: URGN
Reported as of: 22 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 10:03:57 UTC
Prior SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Daniel George Wildman filed Form 4 for UroGen Pharma Ltd. (URGN) on 24 Jun 2026.

Key facts

This page summarizes Daniel George Wildman's Form 4 filing for UroGen Pharma Ltd. (URGN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 10:03.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001952679 Primary reporting owner

Wildman Daniel George

Relationship: Director
Address: 400 ALEXANDER PARK DRIVE, PRINCETON
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Stock Option (right ot buy)

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price: $34.99
Footnotes: F1

URGN transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +8,000
Change %
Price: $0.000000^*
Shares after: 8,000
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

Footnote F3

The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.